Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study.
LAS VEGAS, Aug. 25, 2023 /PRNewswire/ -- JanOne (Nasdaq:JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "Best Abstract" award for reporting that JanOne's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function.
Read more at prnewswire.com